PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2007
CASE
AUTH/1976/3/07 Sanofi

AUTH/1976/3/07: GP complaint about Acomplia ad and alleged breach of undertaking (No breach)

A GP alleged an Acomplia journal ad implied weight-independent effects on cardiometabolic risk factors and encouraged prescribing beyond the obesity indication. Panel…

2007
CASE
AUTH/1963/2/07 GlaxoSmithKline

AUTH/1963/2/07: Independent nurse advisor v GlaxoSmithKline (Diabetes Patient Review Service) – No breach

Complaint alleged a GSK representative accessed patient data and selected patients for a diabetes clinic. Panel found no evidence of access to…

2006
CASE
AUTH/1936/12/06 Schering Health Care

AUTH/1936/12/06: Schering Health Care – Public LARC advert and website found unbalanced, indirectly promoting Mirena (Clause 20.2)

Marks & Spencer magazine feature and linked website on LARC were ruled unbalanced by favouring the IUS (only Mirena in UK), encouraging…

2006
CASE
AUTH/1918/11/06 Amgen ⭐ Case of the Week

AUTH/1918/11/06: Amgen voluntary admissionβ€”Aranesp branded materials visible to the public at patient conference

Amgen admitted Aranesp (POM) branded materials were briefly displayed at a National Kidney Foundation conference accessible to patients/public. Panel ruled breaches of…

2006
CASE
AUTH/1859/6/06 Merck Sharp & Dohme

AUTH/1859/6/06: Anonymous employees v Merck Sharp & Dohme (DEXA service, grants and migraine reviews) – no breach on appeal

Anonymous employees alleged DEXA scanner placements were linked to Fosamax promotion, plus ROI on grants and migraine β€œswitch” programmes. Panel found breaches,…

2018
CASE
AUTH/3010/1/18 Daiichi-Sankyo UK

AUTH/3010/1/18: Daiichi-Sankyo ruled in breach for omitting key SPC warning in Lixiana (edoxaban) promotional guides; corrective statement and recovery required

Daiichi-Sankyo’s Lixiana prescriber guides omitted an SPC warning on reduced efficacy in NVAF patients with high creatinine clearance. Ruled misleading/unbalanced (Clauses 7.2,…

2017
CASE
AUTH/2971/8/17 Thame Laboratories

AUTH/2971/8/17: CCG v Thame Laboratories – threatening, misleading letter promoting Thamicarb

Thame sent clinicians a legalistic letter urging them to stop prescribing an unlicensed sodium bicarbonate product and switch to Thamicarb. PMCPA ruled…

2014
CASE
AUTH/2696/1/14 Novo Nordisk

Novo Nordisk: complaint ruled outwith scope of the ABPI Code (AUTH/2696/1/14)

PMCPA recorded the complaint as outwith the scope of the ABPI Code (2012). No breach was found and no case report was…

2013
CASE
AUTH/2660/11/13 HRA Pharma ⭐ Case of the Week

AUTH/2660/11/13: Member of the public v HRA Pharma (ellaOne) – outwith scope, no breach

Complaint about clinical trial disclosure for ellaOne. PMCPA found the matter was outwith the scope of the ABPI Code (2012). No breach…

2006
CASE
AUTH/1847/6/06 Altana Pharma

AUTH/1847/6/06: PCT head of prescribing complaint against Altana over Alvesco positioning and misquoted endorsement

Altana reps were found to have misrepresented a PCT prescribing lead’s views as endorsing Alvesco’s place in therapy and used an unapproved…

2006
CASE
AUTH/1795/2/06 Merck Sharp & Dohme

MSD held responsible for third‑party email banner missing generic name (Maxalt) – AUTH/1795/2/06

A GP complained that an eMIMS email banner promoted β€œMAXALT” without the non‑proprietary name adjacent. Even though a third party added the…

2007
CASE
AUTH/2026/7/07 Boehringer Ingelheim

Boehringer Ingelheim: Actilyse press release implied unequivocal mortality benefit (AUTH/2026/7/07)

A global Actilyse press release on a corporate website discussed mortality figures in a way that implied an unequivocal effect on death,…

2006
CASE
AUTH/1812/3/06 Bayer

AUTH/1812/3/06: Pfizer v Bayer β€” SortEDin10 campaign and BBC celebrity interview promoted Levitra to the public

A Bayer-sponsored ED awareness campaign used a celebrity spokesperson. In a BBC interview he compared Viagra, Cialis and Levitra, implying Levitra worked…

Merck Sharp & Dohme ⭐ Case of the Week

MSD rep’s Chinese restaurant meeting: unclear educational content and unsuitable venue led to Clause 2 breach

Anonymous photos alleged doctors and wives entertained at a Chinese restaurant. With no agenda/invitation and a public venue, the Panel found the…

2006
CASE
AUTH/1861/7/06 Ferring Pharmaceuticals

Anonymous v Ferring (AUTH/1861/7/06): Polo ground sponsorship signage – no breach

Anonymous complaint about Ferring logo boards at a polo ground. Panel found the signage was non-promotional and the complaint lacked detail; no…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training